Cibus Genetics LLC is a biotechnology company. It develops products in agriculture and specialty chemicals. The company was founded by Peter Beetham in 2001 and is headquartered in San Diego, CA.

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the forefront of developing therapies for rare and orphan diseases. The Company has a robust pipeline of novel, first-in-class, small molecules called pharmacological chaperones for the treatment of lysosomal storage diseases (LSDs). These chaperones may offer a dual-treatment approach for Fabry, Pompe, Gaucher and other LSDs. As orally administered monotherapy agents, pharmacological chaperones are designed to bind to, stabilize and increase the activity of a patient’s own misfolded enzyme. In combination with enzyme replacement therapy (ERT), pharmacological chaperones may improve the uptake of the infused enzyme and potentially improve ERT outcomes.

Genfleet Therapeutics (Shanghai), Inc. is a company headquartered in Shanghai, China. The firm provides research and development services in discovering drugs. It was founded in 2017 by Qiang Lü and Jiong Lan. Jiong Lan has been the CEO since the inception date.\nThe company says this about itself: GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies, is dedicated to serving significant global unmet medical needs in oncology and immunology. Based on the deep understanding of disease biology and translational medicine, GenFleet's proprietary and fully integrated R&D platform highlights multiple cutting-edge products with novel mechanisms and global IP. Since its inception in 2017, GenFleet has built up industry-leading capabilities and expertise in developing novel drug candidates - both small molecules and biologics. Its pipeline includes over 10 programs, many of which have entered multi-regional clinical trials across China (including Taiwan), the United States, Europe and Australia. To date, GenFleet has over 5 clinical studies encompassing IND stage to phase II studies and completed co-development partnerships with a number of publicly listed companies worldwide. GenFleet is expected to progress additional programs into the clinic, as well as transition from a clinical stage biotech company into a commercial stage biopharmaceutical company in the next 3-5 years.

Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of small molecule drugs. Its products include original medicine such as Chidamide, Chiglitazar, Chiauranib. It also engages in technological licensing. The company was founded by Xian Ping Lu and Zhi Qiang Ning on March 21, 2001 and is headquartered in Shenzhen, China.

Zhejiang Jinfang Pharmaceutical Co., Ltd., established on 2018-04-08, Business scope includes pharmaceutical research and development;Transfer of self-owned technological achievements,And provide relevant technical consultation and technical services;Health Management Consulting Services(Do not engage in medical treatment,treat,psychological counseling);Goods and technology import and export business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

At the beginning of the twentieth century, tuberculosis was one of the UK’s most urgent health problems. A royal commission, entitled The Royal Commission Appointed to Inquire into the Relations of Human and Animal Tuberculosis, was set up in 1901. It aimed to find out whether tuberculosis in animals and humans was the same disease and whether animals and humans could infect each other. This page describes how, by 1919, the Commission had evolved into the independent Medical Research Council.

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2018, the company has one approved drug (see the Products section below).

Institut National de la Sant? et de la Recherche M?dicale provides medical services. The firm specializes in biomedical research and public health research. The company is headquartered in Paris, Cedex, France.

Danisco US, Inc. manufactures synthetic resins, synthetic rubbers and industrial chemicals. The company is headquartered in Wilmington, DE.

Arcadia Biosciences is an agricultural technology company focused on developing products that benefit the environment and human health. The company uses advanced screening, breeding and biotechnology techniques (both GM and non-GM) to create value for consumers, processors and farmers. Arcadia’s agronomic performance traits, which include nitrogen use efficiency, water use efficiency, salt tolerance, heat tolerance, and herbicide tolerance, are all aimed at making agricultural production more economically efficient and environmentally sound. Arcadia’s nutrition products create healthier ingredients and whole foods. Arcadia has granted more than 70 technology licenses worldwide to major seed and consumer product companies. The company was named one of MIT Technology Review's 50 Smartest Companies (2014) and has been recognized by AlwaysON as one of the GoingGreen Silicon Valley Global 200 (2011 and 2012).

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Genopsy Co., Ltd. is a company headquartered in Seoul, the South Korea, that manufactures magnetic nanostructures for detecting and isolating circulating tumor cells. It was founded in 2017. Yeong-Nam Jo is currently the CEO of the firm.

Rescue Hearing aims to develop technology that helps in the field of hearing loss treatment and prevention.

SurExam Bio-Tech Co., Ltd. provides personalized medical system solutions focused on tumor molecular diagnostic products and clinical medicine testing services. Its products include medical kits. It also provides medical testing services. The company was founded on November 28, 2006 and is headquartered in Guangzhou, China.

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.